MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
REDWOOD CITY, Calif., March 01, 2018 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 |
| International | 720 634 2938 | |
| Passcode | 3990608 | |
| Live Webcast: | Codexis IR Website | |
| The webcast will be archived for 30 days. | ||
| Replay: | U.S. | 855 859 2056 |
| International | 404 537 3406 | |
| Passcode | 3990608 | |
| The replay will be available for 48 hours | ||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of high-value industrial applications, including as biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables significant improvements in protein performance meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial scale implementations of biocatalytic processes. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
